Monthly Archives: July 2007

Amgen tries its hand at venture capital

Over the past ten years a number of large pharmaceutical and biotechnology companies have established venture funds to help small start-up biotechnology companies. The aim of these funds is to find new ideas, products and technology platforms to supplement internal … Continue reading

Leave a Comment

Filed under acquisitions, Venture Capital

Hedge funds get a taste for biotechnology companies

Biotechnology companies and hedge funds seem odd bedfellows. Biotechnology companies operate on time frames frequently stretching into decades, hedge funds typically operate on time frames measured in days. So why are some hedge funds becoming involved in the biotechnology sector? … Continue reading

Leave a Comment

Filed under Thought pieces

Biopharmaceutical partnering in China

China has become an attractive place for foreign investment in research and development, including the biopharmaceutical sector. A report by the US National Science Foundation in 2004 indicated that between 1994 and 2001 American multinational companies quadrupled their research and … Continue reading

Leave a Comment

Filed under Thought pieces

Biotechnology beyond the US

US inventors have continued to dominate biotechnology innovation since the first commercialisation of biotechnology in the USA in the mid-1980s. Material analysed from Silico Research’s database of 22,000 biotechnology-related patents filed at the USPTO indicates that the USA continues to … Continue reading

Leave a Comment

Filed under Research

AstraZeneca’s acquisition of Medimmune

On April 23 2007 AstraZeneca announced it’s acquisition of MedImmune for $15.6 billion. At least 20 companies had expressed an interest in acquiring MedImmune before AstraZeneca stepped in. The deal brings to AstraZeneca an additional 45 projects to its research … Continue reading

Leave a Comment

Filed under Thought pieces

South Korea’s biopharmaceutical patent footprint a year on from Hwang

A year on from the indictment of Hwang Woo-Suk for his embezzlement of research funds and faking of stem cell results how has the South Korean biotechnology developed and what prospects are there for biopharmaceutical partnering there today? Signs are … Continue reading

Leave a Comment

Filed under Research

Johnson & Johnson turns to internal venturing

In a move designed to encourage collaborative ventures between its 230 subsidiaries internal Johnson & Johnson has recently set up an Internal Ventures Group. Until now Johnson & Johnson had allowed its acquired companies to function largely autonomously in the … Continue reading

Leave a Comment

Filed under Thought pieces

GlaxoSmithKline announces Chinese neurology research centre

GlaxoSmithKline has announced a new Chinese research and development centre to add to its 32 research sites around the world. The centre is to be based in Shanghai and will be focused on the development of drugs to treat neurodegenerative … Continue reading

Leave a Comment

Filed under Thought pieces

China’s biopharmaceutical patent footprint

Since 1997 Chinese based inventors have slowly increased their filing for biopharmaceutical-related patents with the American USPTO, reaching a peak in 2003. While the proportion of Chinese inventors filing for biotechnology-related patents with the USPTO remain small by comparison with … Continue reading

Leave a Comment

Filed under Research

Tykerb’s implications for partnerships

On March 13 2007 GlaxoSmithKline’s cancer drug Tykerb (lapatinib ditosylate) was approved by the FDA for the treatment of patients with advanced or metastatic breast cancer. Targeted to patients who carry the HER2 gene, the drug is to be administered … Continue reading

Leave a Comment

Filed under Thought pieces